Curvilinear Association Between Framingham Steatosis Index and Chronic Kidney Disease: a Nationwide Cross-sectional Study

Overview

Journal Front Med (Lausanne)

Date 2025 Jan 29

PMID 39876873

Authors

Chunqi Jiang

Bo Wang

Jun Wang

Yinuo Qu

Xin Zhang

Affiliations

Soon will be listed here.

Abstract

Introduction: Fatty liver disease is potentially linked to chronic kidney disease (CKD), yet the association between the Framingham Steatosis Index (FSI) and CKD remains uncharted. Our study thoroughly investigated the correlation between FSI and CKD, aiming to elucidate the underlying links between these two conditions.

Methods: The relationship between FSI and CKD was evaluated using a weighted multivariate logistic regression model, and the curvilinear relationship between FSI and CKD was explored through smooth curve fitting. We engaged a recursive partitioning algorithm in conjunction with a two-stage linear regression model to determine the inflection point. By conducting stratified analyses, the heterogeneity within subpopulations was explored.

Results: In the fully adjusted Model 3, which accounted for all covariates, the odds ratios (ORs) (95% CI) for the association between FSI and CKD were 1.01 (0.97, 1.06), indicating no significant statistical association. Sensitivity analysis confirms the stability of the relationship between FSI and CKD. Smooth curve fitting discloses a non-linear association between FSI and CKD. The two-piecewise linear regression model, applied to explore this non-linearity, identified an inflection point at an FSI value of -3.21. Below this threshold, the OR (95% CI) was 0.25 (0.17, 0.37), signifying an inverse correlation between FSI and CKD. Above the inflection point, the OR (95% CI) was 1.19 (1.13, 1.25), suggesting a positive correlation. In the stratified curve analysis, the results were essentially consistent with the overall findings, except for the subgroups with BMI > 30 and age > 50.

Conclusion: We found a curvilinear relationship between FSI and CKD.

References

Spoto B, Pisano A, Zoccali C . Insulin resistance in chronic kidney disease: a systematic review. Am J Physiol Renal Physiol. 2016; 311(6):F1087-F1108. DOI: 10.1152/ajprenal.00340.2016. View

Chen J, Mao X, Deng M, Luo G . Validation of nonalcoholic fatty liver disease (NAFLD) related steatosis indices in metabolic associated fatty liver disease (MAFLD) and comparison of the diagnostic accuracy between NAFLD and MAFLD. Eur J Gastroenterol Hepatol. 2023; 35(4):394-401. PMC: 9951794. DOI: 10.1097/MEG.0000000000002497. View

Agidew M, Abebe E, Muche Z, Mengstie M, Mulu A, Admasu F . Evaluation of liver function biomarkers, blood pressure, and anthropometric parameters among chronic kidney disease patients: Laboratory-based cross-sectional study in Northwest Ethiopia. Metabol Open. 2023; 19:100254. PMC: 10480547. DOI: 10.1016/j.metop.2023.100254. View

Huang X, Wen S, Huang Y, Huang Z . Gender differences in the association between changes in the atherogenic index of plasma and cardiometabolic diseases: a cohort study. Lipids Health Dis. 2024; 23(1):135. PMC: 11075304. DOI: 10.1186/s12944-024-02117-w. View

Mori K, Tanaka M, Sato T, Akiyama Y, Endo K, Ogawa T . Metabolic dysfunction-associated steatotic liver disease (SLD) and alcohol-associated liver disease, but not SLD without metabolic dysfunction, are independently associated with new onset of chronic kidney disease during a 10-year follow-up period. Hepatol Res. 2024; . DOI: 10.1111/hepr.14097. View

Li Z, Xu Z, Xuan C, Xu H . Association between waist triglyceride index, body mass index, dietary inflammatory index, and triglyceride- glucose index with chronic kidney disease: the 1999-2018 cohort study from NHANES. Front Endocrinol (Lausanne). 2024; 15:1390725. PMC: 11330799. DOI: 10.3389/fendo.2024.1390725. View

Lee H, Ro H, Jung J, Chang J, Chung W, Kim A . The Fatty Liver Index's Association with Incident Chronic Kidney Disease in Korean Middle-Aged Adults: A Community-Based Cohort Study. J Clin Med. 2024; 13(6). PMC: 10971018. DOI: 10.3390/jcm13061616. View

Del Turco S, Gaggini M, Daniele G, Basta G, Folli F, Sicari R . Insulin resistance and endothelial dysfunction: a mutual relationship in cardiometabolic risk. Curr Pharm Des. 2012; 19(13):2420-31. DOI: 10.2174/1381612811319130010. View

Chambers D, Ocariz J, McGuirk M, Blount B . Impact of cigarette smoking on volatile organic compound (VOC) blood levels in the U.S. population: NHANES 2003-2004. Environ Int. 2011; 37(8):1321-8. DOI: 10.1016/j.envint.2011.05.016. View

10.

Han A, Lee H . Comparison of the Diagnostic Performance of Steatosis Indices for Discrimination of CT-Diagnosed Metabolic Dysfunction-Associated Fatty Liver Disease. Metabolites. 2022; 12(7). PMC: 9323223. DOI: 10.3390/metabo12070664. View

11.

Goncharov N, Popova P, Avdonin P, Kudryavtsev I, Serebryakova M, Korf E . Markers of Endothelial Cells in Normal and Pathological Conditions. Biochem (Mosc) Suppl Ser A Membr Cell Biol. 2020; 14(3):167-183. PMC: 7553370. DOI: 10.1134/S1990747819030140. View

12.

. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021; 100(4S):S1-S276. DOI: 10.1016/j.kint.2021.05.021. View

13.

Cho Y, Kim M, Kim Y, Jung C, Lee W, Park J . Predictive value of the Framingham steatosis index for cardiovascular risk: a nationwide population-based cohort study. Front Cardiovasc Med. 2023; 10:1163052. PMC: 10391153. DOI: 10.3389/fcvm.2023.1163052. View

14.

Brar A, Markell M . Impact of gender and gender disparities in patients with kidney disease. Curr Opin Nephrol Hypertens. 2019; 28(2):178-182. DOI: 10.1097/MNH.0000000000000482. View

15.

Li C, Lin Y, Luo R, Chen S, Wang F, Zheng P . Intrarenal renin-angiotensin system mediates fatty acid-induced ER stress in the kidney. Am J Physiol Renal Physiol. 2015; 310(5):F351-63. PMC: 4971807. DOI: 10.1152/ajprenal.00223.2015. View

16.

Foreman K, Marquez N, Dolgert A, Fukutaki K, Fullman N, McGaughey M . Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016-40 for 195 countries and territories. Lancet. 2018; 392(10159):2052-2090. PMC: 6227505. DOI: 10.1016/S0140-6736(18)31694-5. View

17.

Qin Y, Xuan L, Deng Y, Wang F, Liu B, Wang S . Triglyceride-glucose index and mortality risk in individuals with or without chronic kidney disease: Insights from a national survey of United States adults, 1999-2018. Nutr Metab Cardiovasc Dis. 2024; 34(8):1994-2001. DOI: 10.1016/j.numecd.2024.04.003. View

18.

Pizzarelli F, Basile C, Aucella F, Dattolo P . Chronic kidney disease in the elderly and frail patient: perspectives with opinions and comments. J Nephrol. 2023; 36(6):1565-1570. DOI: 10.1007/s40620-023-01676-y. View

19.

Xu C, Liang J, Xu S, Liu Q, Xu J, Gu A . Increased serum levels of aldehydes are associated with cardiovascular disease and cardiovascular risk factors in adults. J Hazard Mater. 2020; 400:123134. DOI: 10.1016/j.jhazmat.2020.123134. View

20.

Li X, Wang L, Zhou H, Xu H . Association between weight-adjusted-waist index and chronic kidney disease: a cross-sectional study. BMC Nephrol. 2023; 24(1):266. PMC: 10494374. DOI: 10.1186/s12882-023-03316-w. View